![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Han JY, Choi JS, Chun JM, Park HD, Lee SY, Kim CH, et al 2009. Pregnancy outcome of women transfused during pregnancy with blood products inadvertently obtained from donors treated with acitretin. Journal of Obstetrics and Gynaecology 29:694–697.
- Nava-Ocampo AA, Koren G. 2007. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach. Clinical Obstetrics and Gynecology 50:123–131.
- Park HD, Kim HK, Kim JW, Kim DW, Lee JH, Huh W, et al 2008. Evaluation of the transfusion safety of blood products and determination of plasma concentrations of acitretin and etretinate in patients receiving transfusions. Transfusion 48:2395–2400.
- Sturkenboom MC, de Jong-Van Den Berg LT, van Voorst-Vader PC, Cornel MC, Stricker BH, Wesseling H. 1994. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. British Journal of Clinical Pharmacology 38:229–235.